Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[225Ac]-FPI-2059 in NTSR1-expressing solid tumors
NCT05605522Phase 1Terminated
- Sponsor
- 3B Pharmaceuticals GmbH
- Start
- Feb 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of 3BP-227 in pancreatic ductal adenocarcinoma (PDAC), head and neck squamous cell carcinoma (HNSCC), colorectal cancer (CRC) and 4 more (2 arms), sponsored by 3B Pharmaceuticals GmbH. Primary endpoints: Incidence of Adverse Events, Maximum Tolerated Dose and 1 more. Started Feb 2023; status: terminated.
02
Drugs
3BP-227
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)head and neck squamous cell carcinoma (HNSCC)colorectal cancer (CRC)gastric cancer (GC)Ewing sarcoma
Beyond the preview
Go deeper on NCT05605522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605522.